Stockscreener 앱 받기
1.25
0.79%
-0.01
시장 영업 전:
1.27
0.02
+1.60%
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
BioXcel Shareholder Notice - TMX Newsfile
BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI: IGALMI targets a vast at-home market for acute agitation, with launch readiness for 2027 - TradingView
Transcript : BioXcel Therapeutics, Inc.Special Call - marketscreener.com
BTAI (BioXcel Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares gain 7.48 percent on upbeat investor reaction.NCAV - Xã Thanh Hà
BTAI BioXcel Therapeutics Inc. gains 7.48 percent after posting narrower than expected Q4 2025 EPS results. - Cổng thông tin điện tử tỉnh Tây Ninh
BioXcel Therapeutics, Inc. Enters Fourth Amended and Restated Registration Rights Agreement With Oaktree Investors - Minichart
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - Sahm
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting - 富途牛牛
BioXcel Therapeutics issues warrants to lenders as part of credit agreement amendment - Investing.com
Bioxcel Issues Warrants in Private Equity Financing Deal - TipRanks
BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants - Stock Titan
BioXcel to detail IGALMI launch strategy ahead of FDA decision By Investing.com - Investing.com Australia
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Insider Monkey
BioXcel to detail IGALMI launch strategy ahead of FDA decision - Investing.com
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI) - The Globe and Mail
H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary D - GuruFocus
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia
Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com
BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada
BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - Sahm
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
0.67%
2.13%
자본화:
|
볼륨(24시간):